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ABSTRACT
Introduction: There is limited literature on
treatment patterns, healthcare resource utiliza-
tion (HRU), and costs among patients who
transition from once-monthly paliperidone
palmitate (PP1M) to once-every-3-month
paliperidone palmitate (PP3M) in a real-world
setting. Hence, this study compared treatment
patterns, HRU, and costs 12-month pre- and
post-PP3M transition among Veteran’s Health
Administration (VHA) patients with
schizophrenia.
Methods: Patients with schizophrenia (aged
C 18 years) who initiated PP1M and transitioned
per on-label criteria to PP3M (no treatment gap
of[45 days in PP1M during the 4 months prior,
same dose strength of the last two PP1M claims,
and appropriate dose conversion from last PP1M
to first PP3M claim) from January 2015 to March
2017 were included from the VHA database. The
first transition date to PP3M was identified as the
index date. Patients were required to have
12-month pre- and post-PP3M continuous health
plan eligibility. Outcomes were compared using
the Wilcoxon-signed rank and McNemar’s test,
appropriately.
Results: The study included 122 patients [mean
(SD) age: 54 (13.7) years]. Pre- and post-PP3M
transition, 64.8% and 61.5% of patients were
adherent (proportion of days covered C 80%) to
PP1M and PP3M, respectively. Comparison of
HRU outcomes pre- and post-PP3M transition
exhibited lower all-cause outpatient (37.5 vs.
31.1, p\0.0001) and pharmacy visits (56.1 vs.
46.7, p\0.0001). Similar trends were seen for
mental health and schizophrenia-related out-
patient and pharmacy HRU. Comparison of cost
outcomes resulted in lower all-cause outpatient
($27,221 vs. $22,356, p = 0.0033), higher phar-
macy ($16,349 vs. $17,003, p = 0.0076), lower
total medical ($35,834 vs. $28,900, p = 0.0257),
and no difference in total costs ($52,183 vs.
$45,903, p = 0.3118). Similar trends were seen
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for mental health and schizophrenia-related
costs.
Conclusions: Transition to PP3M was associ-
ated with a decline in outpatient and pharmacy
visits. All-cause medical cost reduction fully
offset increased pharmacy costs among VHA
patients with schizophrenia who transitioned
from PP1M to PP3M.
Funding: Janssen Scientific Affairs.
Keywords: Antipsychotic agents; Healthcare
costs; Schizophrenia; Medication adherence;
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INTRODUCTION
Schizophrenia is a chronic and debilitating men-
tal illness characterized by recurrent episodes of
acute psychosis alternating with periods of full or
partial remission [1]. It is a serious public health
problem that affects approximately 1% of the US
population and is considered 1 of the 20 leading
causes of disabilities worldwide [2–4]. The esti-
mated prevalence of schizophrenia and related
psychotic disorders in the USA ranges between
0.25 and 0.64% [5]. Among US Veterans, a pooled
prevalence of schizophrenia from 11 veteran
studies was found to be up to 11% [6]. A retro-
spective claims-based study from October 2006 to
September 2011 found nearly 60,000 incident
cases of schizophrenia within the Veterans Affairs
(VA) system [7].
Schizophrenia is considered the costliest men-
tal illness and imposes a disproportionately large
economic burden relative to other mental disor-
ders that have been linked to early onset of the
disease and its chronic nature with persisting
symptoms [2, 4, 8, 9]. Furthermore, schizophrenia
placesa significantburdennotonlyonpatientsbut
also families, caregivers, and the healthcare system
[8]. US veterans with schizophrenia were found to
occupy more hospital beds at any given time than
veterans with any other illness [10]. Additionally, a
recent study conducted in 2017 revealed that the
average annual all-cause total healthcare costs
among US veterans with schizophrenia was
$78,589 and $82,895 for patients treated with
paliperidone palmitate (PP) and oral atypical
antipsychotics (OAAs), respectively [11].
Schizophrenia is characterized by a complex
psychopathology such as a diminished capacity
for learning, working self-care, and interper-
sonal relationships [12]. Furthermore,
schizophrenia patients experience a broad range
of symptoms leading to a loss of function and
autonomy. More than 50% of patients have
intermittent but long-term psychiatric prob-
lems, and approximately 20% have chronic
symptoms and disability [4, 13]. The foundation
of treatment for schizophrenia patients—to
help reduce disease severity and frequency of
acute relapses—consists of antipsychotic (AP)
agents including long-acting injectables (LAIs)
and oral AP therapies (OATs) [14]. Despite the
need for long-term, continuous therapy,
patients often have difficulty with adherence to
oral medication regimens [4, 15]. In 2009, the
FDA approved a monthly atypical long-acting
injectable antipsychotic therapy (LAT) once-
monthly paliperidone palmitate (PP1M). Prior
studies have shown that patients treated with
PP1M had lower inpatient and long-term care
admission and thus lower medical costs com-
pared with patients treated with the first-line
oral antipsychotic therapy [10].
In 2015, the FDA approved once-every-3-
month paliperidone palmitate (PP3M). The
advent of this new reduced dosing frequency
therapy has been found to increase treatment
adherence, and patients were shown to be more
persistent on PP3M treatment [16, 17]. The
administration of PP3M requires fewer clinical
visits and thereby lower hospitalization rates
and ultimately reduced healthcare resource
utilization (HRU) and healthcare costs [16, 17].
In a post hoc analysis comparing median time
to relapse across three different treatment trials,
Weiden et al. discovered that after PP3M dis-
continuation, the time to relapse was much
longer compared with PP1M [18]. Specifically,
the study demonstrated that approximately
50% of patients who withdrew from PP3M were
relapse free for approximately 13 months com-
pared with the 6 months of relapse-free time for
PP1M patients [18]. The findings by Weiden
et al. imply that patients using PP3M remained
stable for a longer period of time compared with
PP1M patients, and PP3M may provide evidence
for risk mitigation of schizophrenia patients
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[18]. However, one study on the Medicaid
population reported no significant difference in
AP adherence, HRU, and costs before and after
PP3M initiation [19]. Due to the availability of
such mixed findings from published literature
and the dearth of real-world evidence on the
efficacy of PP3M, there is a significant need to
authenticate such findings using real-world
evidence. Hence, this study aimed to validate
the existing findings on the effectiveness of
PP3M among patients with schizophrenia by
examining treatment patterns, HRU, and costs
among patients who transitioned from PP1M to




The main objective was to compare treatment
patterns, HRU, and costs related to the
12 months pre- and post-transition from PP1M
to PP3M as per on-label criteria to PP3M among
VHA patients diagnosed with schizophrenia.
Data Source
This was a retrospective cohort study utilizing
data from the Veterans Health Administration
(VHA) from January 1, 2014, to March 31, 2018
(the study period).
The VHA is the largest integrated healthcare
system in the USA. The US Department of
Veterans Affairs estimates that in 2014 there
were slightly over 21 million living US military
veterans. In the same year, the department
provided medical services to * 6 million vet-
erans and to over 700,000 non-veterans. This
included services for active duty and reserve
military personnel, spousal collateral, consulta-
tions and instruction, CHAMPVA workload,
reimbursable workload with affiliates, humani-
tarian care, and occupational immunizations
for employees, such as hepatitis A and B and flu
vaccinations [20].
The VHA Medical Statistical Analysis System
(SAS) data sets are national administrative data
for VHA-provided healthcare utilized primarily
by veterans but also by some non-veterans (e.g.,
employees, research participants). The data sets
are provided in SAS format by fiscal year (Oc-
tober 1–September 30). These data are extracted
from the National Patient Care Database as
maintained by the VHA Office of Information at
the Austin Information Technology Center, the
central repository for VA data. The stability of
VHA data sources allows for superior analysis of
the continuity of care of patients over multiple
years.
No identifiable patient information or med-
ical records were disclosed for the purposes of
this study except in compliance with applicable
law. Since the core study did not involve the
collection, use, or transmittal of individual
identifiable data, institutional review board
approval to conduct this study was not
required.
Study Population
Patients included in the study were aged C
18 years. Those selected had C 1 encounter that
included a schizophrenia diagnosis [Interna-
tional Classification of Diseases, Ninth and
Tenth Revision, Clinical Modification (ICD-9/
10-CM) code: 295.XX (excluding 295.7
schizoaffective disorder), ICD-10-CM: F20.XX,
F21] during the study period (January 1,
2014–March 31, 2018); had initiated treatment
with PP1M between January 1, 2015, and March
31, 2017 (the identification period); and had
continuous health plan enrollment for
12 months pre- and post-follow-up date.
Patients must also have transitioned from PP1M
to PP3M as per on-label criteria during the
identification period. The first dispensing of
PP1M was defined as the PP1M date, and the
index date was defined as the first date of dis-
pensing PP3M. Patients were excluded from the
study if they had evidence of PP3M during the
baseline period.
On-label criteria included patients that
transitioned from PP1M to PP3M and had at
least 4 months of PP1M use prior to initiation of
PP3M with no treatment gap of [ 45 days in
PP1M coverage in the 4 months prior to PP3M
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initiation. Patients were on-label if they had the
same dose strength from the last two PP1M
claims prior to transition to PP3M transition
and had the appropriate dosage conversion
between the last PP1M and first PP3M claims
(78–273 mg, 117–410 mg, 156–546 mg, or
234–819 mg) as per prescribing guidelines.
PP3M dispensations were identified through the
National Drug Codes (NDC; 50458-606-01,
50458-607-01, 50458-608-01, and 50458-609-
01).
Demographic and Baseline Clinical
Characteristics
Patients demographics including age, sex, and
race were assessed. Additionally, clinical char-
acteristics including the Quan-Charlson
comorbidity index (Q-CCI) score, other indi-
vidual comorbidities [including mental health
(MH)-related diagnoses such as post-traumatic
stress disorder, anxiety, tobacco use, bipolar
disorder, any depression disorder, and sub-
stance abuse] and non-MH-related diagnoses
[including obesity, diabetes mellitus, cardio-
vascular disease (CVD)-hyperlipidemia, CVD-
hypertension, and chronic obstructive pul-
monary disease] were recognized using ICD-9-
CM codes [see Supplementary Appendices (S),
Appendix 1]. All ICD-9 diagnostic and proce-
dure codes were mapped to ICD-10 codes based
on the general equivalence mappings (GEMs)
published by the Centers for Medicare and
Medicaid Services (CMS) [21].
Outcome Measures
Outcome measures including treatment patterns,
HRU, and costs during the 12-month pre- and
post-PP3M initiation were measured. Moreover,
treatment patterns among patients who transi-
tioned from PP1M to PP3M were measured as the
proportion of patients prescribed APs [including
any oral, LAI, and short-acting injectable (SAI) (S:
Appendices 2 and 3)] and other MH-related
medications [antidepressants, anxiolytics, and
mood stabilizers (S: Appendix 4)]. Furthermore,
medication adherence was calculated using pro-
portion of days covered (PDC) defined as number
of days in the follow-up period ‘‘covered’’ by
medication divided by follow-up time (i.e.,
12 months) and was reported as C 80% as
adherent and\80% as non-adherent [22]. The
medication possession ratio (MPR) was also used
to assess adherence and was defined as the num-
ber of days of supply (i.e., number of days a pre-
scription is supposed to last) within the entire
exposure to therapy. The exposure was defined as
the number of days between the date of the first
drug fill and the last drug refill plus the number of
days of supply of the last refill. The MPR was then
computed as the sum of the days of supply divi-
ded by the exposure to therapy.
All-cause, MH-related, and schizophrenia-
related HRU (e.g., inpatient stays, outpatient
pharmacy visits, outpatient visits, inpatient
length of stay) and costs (e.g., inpatient, out-
patient, pharmacy, total medical, and total
costs) were assessed and compared during the
12-month pre- and post-PP3M transition. Med-
ical claims were considered MH-related if there
was a mental health disorder (S: Appendix 5)
and/or schizophrenia diagnosis (as defined pre-
viously) in any position on the claim. MH-re-
lated pharmacy costs included costs for any AP
(S: Appendices 2 and 3) and/or other MH-re-
lated (S: Appendix 4) medications. Medical costs
were considered schizophrenia-related if there
was a schizophrenia diagnosis in any position
on the claim. Schizophrenia-related pharmacy
costs included costs for any AP (S: Appendices 2
and 3). All costs were adjusted to 2017 US dol-
lars using the medical care component of the
consumer price index (CPI).
Statistical Analysis
Demographics and baseline clinical character-
istics were examined descriptively among PP1M
users who transitioned to PP3M as per on-label
criteria. To compare the 12 months of pre- and
post-PP3M transition, outcomes such as treat-
ment patterns, HRU, and healthcare costs were
analyzed using the Wilcoxon signed-rank test
for continuous variables and McNemar’s test for
categorical variables. The level of significance
was set at a = 0.05. All the analyses were con-
ducted using SAS statistical software (version
9.3, SAS Institute, Cary, NC, 2012).
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RESULTS
Based on the inclusion criteria, there were 3627
patients who initiated treatment with PP1M
during the identification period. Among the
3627 patients identified, 122 met the remaining
inclusion/exclusion criteria of transitioning




The average age of on-label PP1M users who
transitioned to PP3M was 54 years. A majority
of the patients belonged to the age group of
55–64 years (36.1%), and 24.6% were C
65 years. Patients were predominantly male
(91.8%) and white (54.1%). The mean Q-CCI
score of schizophrenia patients was 0.9. The
most common MH-related comorbidities were
substance abuse (34.4%) followed by any
depression disorder (33.6%) and tobacco use
(28.7%). Furthermore, the most common non-
MH-related comorbidities were CVD-hyperten-
sion (38.5%) and CVD-hyperlipidemia (38.5%)
followed by diabetes mellitus (26.2%) and obe-
sity (21.3%) (Table 1).
Treatment Patterns During Pre- and Post-
Transition to PP3M
During the pre- and post-transition to PP3M,
the use of antidepressants was significantly
higher in the 12 months pre-PP3M initiation
compared with the 12 months post-PP3M
Patients who initiated treatment with PP1M during the identification period (01 Jan 2015 - 31 March 2017); the first 
dispensing of PP1M was defined as the PP1M date
N=3,627
Patients who transitioned from PP1M to on-label use of PP3M during the identification period (01 Jan 2015-
31MAR2017); the first dispensing of PP3M was defined as the index date
N=167 
Aged ≥18 years as of index date
N=122 




≥ 1 encounter that included a schizophrenia diagnosis (International Classification of Diseases, 9th/10th Revision, 
Clinical Modification [ICD-9/10-CM]: 295.XX [excluding 295.7 schizoaffective disorder], ICD-10-CM: F20.XX, F21) 
during the study period  
N= 122 
No evidence of PP3M prescription during the baseline period
N=122 
Fig. 1 Patient selection criteria for transition to on-label PP3M. PP1M once-monthly paliperidone palmitate, PP3M once-
every-3-month paliperidone palmitate
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Table 1 Comparison of treatment patterns 12-month pre- and post-PP3M transition among VHA patients treated with
PP1M
Treatment patterns 12-month pre- and
post-PP3M transition
12-month pre-PP3M
transition (N = 122)
12-month post-PP3M
transition (N = 122)
p value*
N (%) N (%)
AP use
Any oral APs 60 (49.2%) 51 (41.8%) 0.0947
Atypical oral APs 57 (46.7%) 48 (39.3%) 0.0947
Any LAI APs 122 (100.0%) 122 (100.0%) –
Atypical LAI APs 122 (100.0%) 122 (100.0%) –
Antidepressants 78 (63.9%) 68 (55.7%) 0.0075*
Anxiolytics 58 (47.5%) 55 (45.1%) 0.5637
Mood stabilizers 57 (46.7%) 53 (43.4%) 0.2850
PDC
PDC by any agent
mean ± SD [median]
0.9 ± 0.1 [0.9] 0.9 ± 0.2 [1.0] 0.7770
C 80% 110 (90.2%) 104 (85.2%) 0.2999
PDC by PP1M
mean ± SD [median
0.8 ± 0.2 [0.8] 0.1 ± 0.2 [0.0] \ 0.0001*
C 80% 79 (64.8%) 0 (0.0%) –
PDC by PP3M
mean ± SD [median]
– 0.8 ± 0.3 [0.9] –
C 80% 75 (61.5%) –
MPR
MPR by any agent
mean ± SD [median]
1.0 ± 0.1 [1.0] 1.0 ± 0.1 [1.0] 0.9264
C 80% 116 (95.1%) 115 (94.3%) 0.7815
MPR by PP1M
mean ± SD [median]
0.8 ± 0.2 [0.9] 0.1 ± 0.2 [0.0] \ 0.0001*
C 80% 91 (74.6%) 4 (3.3%) \ 0.0001*
MPR by PP3M
mean ± SD [median]
– 0.8 ± 0.3 [1.0] –
C 80% 82 (67.2%) –
AP antipsychotic, LAI long-acting injectable, MPR medication possession ratio, PP1M once-monthly paliperidone
palmitate, PP3M once-every-3-month paliperidone palmitate
*Significant at p\ 0.05
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transition period (63.9% vs. 55.7%, p = 0.0075).
There was no significant difference in the use of
any APs, anxiolytics, or mood stabilizers upon
comparison of 12 months pre- and post-PP3M
initiation.
Adherence, as defined by PDC and MPR,
revealed that during the pre-PP3M transition,
64.8% and 74.6% of patients were adherent
(C 80%) to PP1M, respectively. During the post-
PP3M transition, PDC and MPR showed that
61.5% and 67.2% of patients were adherent
(C 80%) to PP3M, respectively (Table 1).
HRU During the Pre- and Post-Transition
to PP3M
During the 12-month pre-PP3M transition,
patients had a significantly higher number of
all-cause outpatient (37.5 vs. 31.1, p\ 0.0001)
and pharmacy visits (56.1 vs. 46.7, p\ 0.0001)
compared with the post-PP3M period. Signifi-
cantly more MH-related outpatient (23.5 vs.
16.0, p\0.0001) and pharmacy visits (48.3 vs.
37.4, p\ 0.0001) were observed for patients
during the pre- vs. post-PP3M transition period.
Similarly, patients had significantly more mean
schizophrenia-related outpatient (15.4 vs. 8.1,
p\0.0001) and pharmacy visits (27.4 vs. 18.7,
p\0.0001) during the pre- vs. post-PP3M
transition (Table 2).
Costs During the Pre- and Post-Transition
to PP3M
Among VHA patients, a significant decrease was
observed for all-cause outpatient costs from pre-
PP3M to post-PP3M transition ($27,221 vs.
$22,356, p = 0.0033). As such, the total all-cause
medical (in- and outpatient) costs significantly
declined from pre-PP3M to post-PP3M transi-
tion ($35,834 vs. $28,900, p = 0.0257). How-
ever, all-cause pharmacy costs were slightly
lower during the pre-PP3M transition compared
with post-PP3M ($16,349 vs. $17,003,
p = 0.0076). As a result, the all-cause total cost
did not result in any significant difference from
pre- to post-PP3M transition ($52,183 vs.
$45,903, p = 0.3118) (Table 2).
A significant decrease from pre-PP3M to
post-PP3M transition was also observed for
mean number of MH-related outpatient costs
($23,120 vs. $17,561, p\0.0001). Total MH-
related medical costs also significantly declined
from pre- to post-PP3M ($31,219 vs. $24,105,
p = 0.0005). However, MH-related pharmacy
costs significantly increased from pre- to post-
PP3M transition ($14,826 vs. $15,999,
p = 0.0067). Therefore, the total MH-related
costs were found to be comparable during the
pre- and post-PP3M transition ($46,045 vs.
$40,104, p = 0.0734) (Table 2).
Furthermore, findings on schizophrenia-re-
lated healthcare costs revealed a similar trend to
all-cause and MH-related costs. Study results
indicated that schizophrenia-related outpatient
costs were significantly higher during the pre-
PP3M transition compared with the post-PP3M
transition ($13,724 vs. $9701, p\ 0.0001).
Total medical costs were also significantly
higher during the pre-PP3M transition ($16,179
vs. $11,255, p = 0.0001). On the other hand,
schizophrenia-related pharmacy costs were
higher during the post-PP3M period ($14,365
vs. $15,793, p = 0.0018). Due to the high phar-
macy costs during the post-PP3M transition, the
total schizophrenia-related healthcare costs
remained similar during the pre- and post-PP3M
transition ($30,544 vs. $27,047, p = 0.3305) as
illustrated in Table 2.
DISCUSSION
This retrospective claims-based study compre-
hensively assessed the treatment patterns and
economic burden of schizophrenia patients that
transitioned from PP1M to PP3M. PP3M is rec-
ommended for use after the initiation of PP1M
and establishment of at least 4 months of
effective treatment [23]. Prior research has
shown that the transition to PP3M was associ-
ated with improved therapy adherence, reduced
hospitalization rates, and thereby reduced HRU
and healthcare costs [16, 17]. However, one
Medicaid study reported no significant differ-
ence in AP adherence, HRU, and costs before
and after PP3M initiation [19]. Due to the
availability of such varied findings from
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Table 2 Comparison of healthcare resource utilization during the 12-month pre- and post-PP3M transition among VHA
patients treated with PP1M







N (%) N (%)
All-cause HRU
Number of patients
Any inpatient stay 25 (20.5%) 23 (18.9%) 0.7150
Any pharmacy visit 122 (100.0%) 122 (100%) –
Any outpatient visit 122 (100.0%) 122 (100%) –
Number of visits (mean ± SD)
Inpatient length of stay (LOS)
[days]
5.7 ± 17.8 4.4 ± 13.9 0.2158
Number of inpatient stays 0.5 ± 1.4 0.5 ± 1.3 0.8947
Number of outpatient visits 37.5 ± 20.4 31.1 ± 22.0 \ 0.0001*
Number of pharmacy visits 56.1 ± 39.2 46.7 ± 35.7 \ 0.0001*
Mental health-related HRU
Number of patients
Any inpatient stay 25 (20.5%) 23 (18.9%) 0.7150
Any pharmacy visit 122 (100.0%) 122 (100%) –
Any outpatient visit 122 (100.0%) 122 (100%) –
Number of visits (mean ± SD)
Inpatient length of stay (LOS)
[days]
5.6 ± 17.6 4.4 ± 13.9 0.2788
Number of inpatient stays 0.4 ± 1.0 0.4 ± 1.1 0.9937
Number of outpatient visits 23.5 ± 10.0 16.0 ± 10.1 \ 0.0001*
Number of pharmacy visits 48.3 ± 35.2 37.4 ± 30.6 \ 0.0001*
Schizophrenia-related HRU
Number of patients
Any inpatient stay 10 (8.2%) 12 (9.8%) 0.6171
Any pharmacy visit 122 (100.0%) 122 (100%) –
Any outpatient visit 115 (94.3%) 110 (90.2%) 0.0956
Number of visits (mean ± SD)
Inpatient length of stay (LOS)
[days]
1.6 ± 7.0 1.4 ± 6.6 0.8672
Number of inpatient stays 0.1 ± 0.7 0.1 ± 0.4 0.9988
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published literature and the scarcity of real-
world evidence on the efficacy of PP3M, this
study set out to address these concerns in a real-
world setting.
The study findings showed that there was an
improvement in clinical outcomes such as the
significant decline of antidepressant use post-
PP3M transition. While previous literature has
not reported a decline in the use of antidepres-
sants associated with PP3M transition, the cur-
rent study warrants further research into the
decline of antidepressants for validation, rea-
sons for discontinuation, and implications of
antidepressant use for HRU and costs.
Table 2 continued







N (%) N (%)
Number of outpatient visits 15.4 ± 5.5 8.1 ± 4.8 \ 0.0001*
Number of pharmacy visits 27.4 ± 29.3 18.7 ± 24.5 \ 0.0001*
All-cause costs (mean ± SD)
Inpatient stay costs $8613 ± $23,358 $6544 ± $22,610 0.2082
Outpatient visit costs $27,221 ± $23,602 $22,356 ± $18,981 0.0033*
Pharmacy costs $16,349 ± $11,028 $17,003 ± $9155 0.0076*
Total medical
(outpatient ? inpatient) costs
$35,834 ± $38,093 $28,900 ± $32,210 0.0257*
Total (medical ? pharmacy) costs $52,183 ± $43,942 $45,903 ± $35,245 0.3118
Mental health-related costs (mean ± SD)
Inpatient stay costs $8099 ± $22,298 $6544 ± $22,610 0.2759
Outpatient visit costs $23,120 ± $19,859 $17,561 ± $16,038 \ 0.0001*
Pharmacy costs $14,826 ± $6787 $15,999 ± $7316 0.0067*
Total medical
(outpatient ? inpatient) costs
$31,219 ± $33,729 $24,105 ± $30,043 0.0005*
Total (medical ? pharmacy) costs $46,045 ± $35,466 $40,104 ± $31,822 0.0734
Schizophrenia-related costs (mean ± SD)
Inpatient stay costs $2455 ± $10,935 $1553 ± $5800 0.8317
Outpatient visit costs $13,724 ± $15,255 $9701 ± $13,230 \ 0.0001*
Pharmacy costs $14,365 ± $6379 $15,793 ± $7250 0.0018*
Total medical
(outpatient ? inpatient) costs
$16,179 ± $21,255 $11,255 ± $15,308 0.0001*
Total (medical ? pharmacy) costs $30,544 ± $21,579 $27,047 ± $16,589 0.3305
HRU healthcare resource utilization, PP1M once-monthly paliperidone palmitate, PP3M once-every-3-month paliperidone
palmitate, SD standard deviation
*Significant at p\ 0.05
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There was also an improvement in HRU with
the observation of a significantly lower number of
all-cause, MH-, and schizophrenia-related outpa-
tient and outpatient pharmacy visits post-PP3M
transition. In support of our findings, a 2018
study by DerSarkissian et al. illustrated that vet-
erans had fewer outpatient visits during the post-
PP3M transition [16]. A reason for the reduction
in outpatient and outpatient pharmacy visits
could be the reduction in dosing frequency, as
PP3M is administered once every 3 months as
opposed to the once-monthly PP1M. Further-
more, the added flexibility of the once-every-3-
month dosing option for PP3M leads to improved
adherence, which, in turn, can greatly affect
recovery and quality of life and ultimately reduce
HRU. Several other studies also support the
notion of reduced dosing frequency and its asso-
ciation with improved adherence [24–26]. In
another 2018 study, Lai et al. reported that
patients who switched from PP1M to PP3M were
found to have quality of life benefits due to the
decreased number of visits for injections. A lower
frequency of injections allows for patients to gain
more control of their daily lives and gives patients
fewer reminders of their illness burdens [27]. A
study by Einarson et al. in 2017 found that less
frequent administrations are also associated with
fewer negative effects such as reduced injection
site pain and less disruption of daily activities.
Reduced dosing frequency can also give patients
more time for other activities such as rehabilita-
tion [28]. Additionally, as the administration of
PP3M is required only four times per year,
physicians, nurses, and caregivers are given more
freedom—allowing for a better use of resources in
the overburdened healthcare system [28, 29].
Overall, nonadherence to treatment is prevalent
among patients with schizophrenia undergoing
antipsychotic therapy, and nonadherence pre-
sents an increased risk of relapse and hospital-
ization for patients. However, the reduced dosing
frequency of PP3M may greatly benefit patients
not only in terms of HRU but also in providing
the benefit of improved quality of life.
Significantly lower all-cause, MH-, and
schizophrenia-related costs post-PP3M transi-
tion were observed for outpatient and total
medical costs. Furthermore, while the numeric
values for all-cause, MH-, and schizophrenia-
related costs were lower during the post-PP3M
transition compared with the pre-PP3M transi-
tion, the cost difference was not statistically
significant. Despite the offset in total cost, there
could still be some financial impact on payers.
In the similar study by DerSarkissian et al., a
significant decrease was not only observed for
in- and outpatient costs, but also for total costs
during the study’s 6-month post-PP3M transi-
tion compared with the pre-transition period,
which could be indicative of an overall cost
saving during post-PP3M transition. Specifi-
cally, DerSarkissian et al. observed significant
inpatient cost savings of approximately $2300
compared with the non-significant savings of
$2000 in the current study. However, the study
only investigated HRU and costs 6 months pre-
and post-transition to PP3M. The differences in
study times may have been because of the dif-
ferences in findings. A longer study time pre-
and post-transition can accumulate more data
on patients but would introduce more extrane-
ous factors that may influence results. A 2018
claims-based study by Emond et al., using
Medicaid data, elected for a study period of
6 months pre- and 12 months post-transition
and observed an offset in healthcare costs—like
the current study. Emond et al. remarked that if
a 12-month pre-initiation period was used in
the study then HRU and costs could be captured
during a time where patients may not yet have
been stabilized on PP1M. These results and
remarks by Emond et al. warrant future analysis
of study time consideration for pre- and post-
transition periods and how it may affect results.
Additionally, the possible driver for total cost
offset in the current study could be the phar-
macy cost, which was approximately $650
higher during the post-PP3M transition. Brasso
et al. and Daghistani et al. noted that three
doses of PP1M are the equivalent of one PP3M
dose; however, the administrations are reduced
by 66%. These studies explain the current
study’s findings where pharmacy costs were
higher during the post-PP3M period leading to
an offset in costs after accounting for other
healthcare costs. Despite this cost offset, PP3M
can provide a clinical benefit to patients in
terms of convenience of dosing frequency,
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which may be associated with improved quality
of life.
Whileclaimsdataareextremelyvaluable for the
efficient and effective examination of healthcare
outcomes, treatment patterns, and HRU and costs,
claims data are collected for the purpose of pay-
ment and not research. Therefore, claims data can
have coding inaccuracies and missing data. With
claimsdata, adherence isevaluatedonthepresence
of a claim and does not indicate if a medication has
been taken as prescribed, especially for oral medi-
cations, and can therefore overestimate patient
adherence. In addition, cost results may only be
generalizable to the US because the data included
VHA patients in the US and medical costs were
adjusted to US dollars. It should also be noted that
while the standard deviations for costs were large,
thiscanbeattributed to thesmall sample sizeor the
scale of costs. Furthermore, the current study only
focused on the direct HRU and costs for patients
with schizophrenia pre- and post-PP3M transition.
Indirect cost benefits of PP3M transition for
patients with schizophrenia such as productivity
and employment may be of interest for future
studies.
The baseline of 12 months may not capture
the first PP1M use for the subset of patients that
may have been on PP1M much longer. The pre-
post study design comes with limitations such
as that the differences in the outcome of inter-
est may not be fully attributable to the specific
intervention. Moreover, the study did not
account for changes in patient characteristics
before and after the PP3M use when assessing
the change in outcomes. While the duration of
effect for LAIs is independent of further action
by patients, future research using longer follow-
up times may help to confirm findings on PP3M
transition benefits [30].
Nevertheless, the study’s strength comes from
the use of patients as their own controls. Finally,
results may not be generalizable to the entire US
population, as the study only included VHA
patients who sought out healthcare through the
VHA system, wherein patients may have different
characteristics and comorbidities compared with
the general population. Patients in the VHA sys-
tem are also predominantly males and of lower
socioeconomic status, and a high proportion of
patients are aged 55 years and older. Furthermore,
because the current study focused on the transi-
tion of PP1M to PP3M per an on-label basis,
results may not be generalizable outside of the
sample used. Moreover, the smaller sample size
may be attributed to the fact that oral antipsy-
chotic therapies are considered the first-line of
therapy for patients with schizophrenia before
LAI initiation [10, 31]. Last, as stated previously,
PP3M is generally recommended after the effec-
tive establishment of PP1M treatment for at least
4 months [23].
CONCLUSIONS
This study demonstrated the transition to PP3M
from PP1M was associated with a significant
decline in all-cause outpatient and pharmacy
visits among VHA patients with schizophrenia.
Furthermore, there was a reduction in all-cause
medical costs fully offsetting the incremental
all-cause pharmacy costs from 12-month pre-
and post-PP3M transition. These findings exhi-
bit the potential improvement of clinical and
economic outcomes when considering ade-
quately treated PP1M patients for PP3M ther-
apy. In addition, a substantial decrease was
observed in concomitant medication use, such
as antidepressants, among patients during the
post-PP3M transition. While this analysis was
limited to the outcomes assessable in the claims
database, future studies should assess the
impact of the every-3-month therapeutic option
on humanistic outcomes such as quality of life
for those patients maintained on PP1M.
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